tug of war, money

To successfully launch rare disease drugs, with their small patient populations and high costs, pharma manufacturers need to get payers involved in discussions as soon as possible to ensure patient access.


Companies are overcoming challenges to develop and launch rare disease medicines faster, and data shouldn’t be an obstacle.

Maria Fontanazza

Ten years after the Ice Bucket Challenge there are few treatment options for ALS, a fatal neurological disease for which there is no cure. A new public-private collaboration is working to change this.


M&A deal growth, the AI revolution, and the market surge of GLP-1 weight-loss medicines represent a trio of hot trends propelling the biopharmaceutical industry.

Alister Campbell, Dotmatics

How artificial intelligence is reshaping drug discovery and development.

Jesse Mendelsohn, Model N

Model N reported during first-half 2024 that 94 percent of pharma executives are taking steps to prepare their revenue management programs for upcoming regulatory changes, with 44 percent specifically calling out Medicaid as a concern.

Dan Ayala, Dotmatics

Data integrity is an ongoing concern across all R&D organizations, no matter what part of the research lifecycle they’re navigating. These concerns extend beyond the potential for delayed timelines or cost overruns.

Kristin Pothier, KPMG

How is M&A activity faring in 2024 specifically in the pharma/biopharma sector?

Franco Negron, Simtra

A look at trends impacting biopharma and Simtra’s business model.